BY: MANAR IBRAHIM MOHAMED IBRAHIM MOSA
BY: Nouran abdo abdo elezaby
Introduction
Illustrated mechanism of action
Examples of Medication Brand Names (with Images)
Indication
Side Effects
Precautions & Contraindications
Monographs
Reference
1) By / Afnan kamal Ali Fahmy
Deferoxamine (DFO), also known as Desferal , is a chelating agent used to treat iron and aluminum toxicity. It binds excess metals in the body, forming complexes that are excreted in urine. DFO is mainly used for conditions like iron overload in thalassemia patients and acute iron poisoning. It is given by injection and plays a key role in preventing organ damage caused by metal accumulation.
Deferoxamine works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming ferrioxamine, a stable complex which is eliminated via the kidneys. 100 mg of deferoxamine is capable of binding approximately 8.5 mg of trivalent (ferric) iron. Deferoxamine works in treating aluminum toxicity by binding to tissue-bound aluminum to form aluminoxamine, a stable, water-soluble complex. The formation of aluminoxamine increases blood concentrations of aluminum, resulting in an increased concentration gradient between the blood and dialysate, boosting the removal of aluminum during dialysis. 100 mg of deferoxamine is capable of binding approximately 4.1 mg of aluminum.
Examples of Medication Brand Names
Desferal ( Defroxamine )
Mechanism & How to reduce side effects
Indications and Usage for Deferoxamine
1- Acute Iron Intoxication
Deferoxamine Mesylate for Injection is indicated as an adjunct to standard measures for the treatment of acute iron intoxication.
2- Chronic Iron Overload
Deferoxamine Mesylate for Injection is indicated for the treatment of transfusional iron overload in patients with chronic anemia.
3-Limitations of Use
Deferoxamine Mesylate for Injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder).
Frequency Not Defined
Injection site reactions (eg, localized irritation, induration, infiltration, pain, erythema, wheal formation, eschar, burning, swelling, pruritus, crust, vesicles, local edema); these may be associated with systemic allergic reactions .
Systemic reactions (eg, abdominal pain, arthralgia, asthma, fever, headache, myalgia, nausea, vomiting)
Hypersensitivity reactions (eg, anaphylactic reaction with or without shock, angioedema, generalized rash, urticaria) .
OCULAR AND AUDITORY DISTURBANCES
Ocular and auditory disturbances reported when therapy administered over prolonged periods of time, at high doses, or in patients with low ferritin levels; in most cases, both ocular and auditory disturbances were reversible upon immediate cessation of treatment
Precautions & Contraindications
Contraindications
1-Known hypersensitivity to the active substance.
2-Patients with severe renal disease or anuria
Warnings and Precautions
Hypersensitivity Reactions: More common with rapid intravenous infusion. Administer intramuscularly or by slow subcutaneous or intravenous infusion. (5.1)
Auditory and Ocular Toxicity: Have been reported when administered over prolonged periods of time, at high doses, or in patients with low ferritin levels. (5.2)
Renal Toxicity: Cases of acute renal failure, renal tubular disorders and increase in serum creatinine have occurred. Monitor patients for changes in renal function. (5.3)
Respiratory Toxicity: Acute respiratory distress syndrome has occurred. Risk increased with high intravenous doses. Recommended daily dose should not be exceeded. (5.4)
Growth Suppression: Has occurred in pediatric patients treated with high doses and concomitant low ferritin levels. Dose reduction may partially resume growth velocity to pre-treatment rates. (5.5)
Drug Interactions .
1-Concurrent treatment with prochlorperazine may lead to temporary impairment of consciousness.
2-Imaging results may be distorted due to rapid urinary excretion of Deferoxamine Mesylate for Injection bound gallium-67. Discontinue Deferoxamine Mesylate for Injection 48 hours prior to scintigraphy.
Toxicity
Intravenous LD50 in mouse, rat, and rabbit is 340 mg/kg, 520 mg/kg, and 600 mg/kg, respectively. Subcutaneous LD50 in mouse and rat is 1600 mg/kg and >1000 mg/kg, respectively. Oral LD50 in mouse and rat is >3000 mg/kg and >1000 mg/kg, respectively. Nephrotoxicity, ototoxicity and retinal toxicity have been reported following long-term administration for chronic iron overload.
monograph
Monograph
Reference
https://go.drugbank.com/drugs/DB00746
https://images.app.goo.gl/RbJsZvuUr4eixCts9
https://reference.medscape.com/drug/343722?src=mbl_msp_android&ref=share
https://www.drugs.com/pro/deferoxamine.html
https://go.drugbank.com/drugs/DB00746?utm_source=perplexity
https://www.slideserve.com/issac/iron-chelation-basics?fitview=true#ssShare
Introduction
Calcitriol is the biologically active form of vitamin D and therefore has a more immediate onset of action (maximal effect in <4 d) and a much shorter time for dissipation of effect in the event of toxicity (1–7 d). It is therefore the drug of choice for the treatment of hypoparathyroidism. Calcitriol can also be used prior to surgical parathyroidectomy for treatment of hyperparathyroidism.
Formulations and dose rates
It is available as 250 or 500 ng capsules and is administered orally at an initial dose of 30–60 ng/kg/24 h. If administered at a dose of approximately 7.5 ng/kg/24 h in the 5–7 d preceding surgery for primary hyperparathyroidism, active calcium absorption will be expected in the immediate postsurgical period when the risk of hypoparathyroidism is high.
At lower dose (2.5–3.5 ng/kg/d) calcitriol inhibits PTH secretion and it is this dose that is recommended for renal secondary hyperparathyroidism although studies clearly evaluating its efficacy are lacking. The available capsule size limits the use of this drug at low doses or in small dogs or cats. Regular monitoring of circulating calcium concentration is required using the lowest possible dose to maintain calcium concentration in the lower end of the reference range.
MOA
Mechanism of Action of Calcitriol
Calcitriol, being lipid-soluble, enters target cells through passive diffusion or via the megalin/cubulin system when bound to vitamin D-binding protein (vDBP) .
Binding to Vitamin D Receptor (VDR)
Inside the cell, calcitriol binds to the vitamin D receptor (VDR) in the cytoplasm.
Formation of VDR-RXR Complex
The calcitriol-VDR complex dimerizes with the retinoid X receptor (RXR) to form the active VDR-RXR heterodimer.
Translocation to the Nucleus
The VDR-RXR complex translocates to the nucleus, where it binds to vitamin D response elements (VDREs) in the promoter regions of target genes.
Gene Transcription Regulation
Binding to VDREs leads to the activation or repression of gene transcription, influencing the expression of genes involved in calcium and phosphate metabolism, bone health, and immune function .
Examples of Medication Brand Names
CALCITRON (cap)
DECOSTRIOL (soft cap)
CALCITREX (tab)
Rocaltrol (cap)
FDA-Approved Indications
Systemic calcitriol is FDA-indicated to control hypocalcemia in patients on chronic renal dialysis, secondary hyperparathyroidism in patients with chronic kidney disease not yet on dialysis, and hypocalcemia in patients with hypoparathyroidism and pseudohypoparathyroidism.[2][3][4] In 2009, the FDA approved topical calcitriol ointment to manage mild to moderate plaque psoriasis.[5] According to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, for patients with chronic kidney disease stage 5 on dialysis (CKD G5D) requiring parathyroid hormone (PTH)-lowering therapy, it is suggested to use calcimimetics, calcitriol, or vitamin D analogs. Additionally, in patients within the first 12 months after kidney transplant, with an estimated glomerular filtration rate greater than approximately 30 mL/min/1.73 m2 and low bone mineral density (BMD), treatment with vitamin D, calcitriol, or alfacalcidol should be considered. For pediatric patients, calcitriol may be considered to maintain serum calcium levels within the age-appropriate normal range.[6] According to the Joint American Academy of Dermatology–National Psoriasis Foundation Guideline, topical vitamin D analogs (such as calcitriol) for up to 52 weeks is recommended for mild to moderate psoriasis. However, combination treatments with vitamin D analogs and topical corticosteroids from 3 to 52 weeks are more effective than either agent alone.[7] Alfacalcidol and calcitriol effectively maintain calcium levels and physiological 1,25-dihydroxyvitamin D levels in hypoparathyroidism. However, calcitriol is more potent than alfacalcidol.[8]
Off-Label Uses
Off-label uses for systemic calcitriol include type 1, vitamin D-dependent rickets, or pseudo-vitamin D deficiency rickets.[9][10] Calcitriol is also used off-label for X-linked hypophosphatemia, known as vitamin D-resistant rickets.[11] Off-label use of topical calcitriol ointment includes psoriasis in children and adolescents.[12] Calcitriol has been studied in patients with Friedreich ataxia (FRDA) at a minimum dose of 0.25 μg daily, increasing frataxin levels with minimal adverse effects. However, no significant neurological improvement was observed. Future trials with higher doses, larger patient groups, and longer treatment durations could provide more insight. However, the study had a small sample size, was open-label without a placebo, and excluded 5 patients due to mild hypercalcemia.[13] A study comparing calcipotriol and calcitriol in combination with narrow-band ultraviolet B phototherapy for stable plaque psoriasis showed both treatments effective, with calcipotriol demonstrating earlier plaque clearance and fewer treatment sessions.[14]
Side effect
The most common side effect of calcitriol is high calcium levels (hypercalcemia) (see below), which can be serious.
There may be other side effects of calcitriol that are not listed here. Contact your health care provider if you think you are having a side effect of a medicine.
What are the serious side effects of calcitriol?
While less common, the most serious side effects of calcitriol are described below, along with what to do if they happen.
Severe Allergic Reactions. Calcitriol may cause allergic reactions, which can be serious. Stop using calcitriol and get help right away if you have any of the following symptoms of a serious allergic reaction.
Breathing problems or wheezing
Racing heart
Fever or general ill feeling
Swollen lymph nodes
Swelling of the face, lips, mouth, tongue, or throat
Trouble swallowing or throat tightness
Itching, skin rash, or pale red bumps on the skin called hives
Nausea or vomiting
Dizziness, feeling lightheaded, or fainting
Stomach cramps
Joint pain
High Calcium Levels (Hypercalcemia). Calcitriol can cause high calcium levels, also called hypercalcemia. Hypercalcemia can lead to serious problems with your kidneys, heart, or bones. Stop using calcitriol and call your health care provider if you have any of the following symptoms.
Precautions &Contraindications
Relative contraindications to calcitriol include patients with increased sensitivity to calcium dysregulation, including arteriosclerosis, cardiac disease, hyperphosphatemia, renal failure, and sarcoidosis. Patients with cardiac disease, especially those taking digoxin, are at an increased risk for cardiac arrhythmias from hypercalcemia and should be dosed conservatively.[26] Patients with renal failure are susceptible to increased risk for vitamin D-induced hypercalcemia, and chronic hypercalcemia may lead to soft tissue calcification, nephrocalcinosis, and other toxicities.
From a preventative lifestyle perspective, accidental exposure, prolonged ultraviolet (UV) sunlight absorption, occlusive dressing use, ocular exposure, and dehydration are contraindications to calcitriol use, as they may increase serum calcium to toxic levels. Photosensitizing agents and UV sunlight may increase the risk of skin tumor formation when combined with topical calcitriol. The topical ointment should not be applied to the face, which may lead to skin irritation. For patients with recent injuries and wounds, increased calcium levels may also occur with topical administration due to the enhanced absorption of calcitriol from occlusive dressings.
As per Endocrine Society guidelines, ectopic production of calcitriol is a less frequent but significant cause of hypercalcemia of malignancy (HCM), particularly in lymphomas. Calcitriol-induced HCM increases calcium and phosphorus absorption from the gastrointestinal tract and enhances osteoclast-mediated bone resorption. Despite glucocorticoid therapy inhibiting the 1α-hydroxylase enzyme to limit calcitriol production, hypercalcemia may persist in these patients. In such cases, adding an intravenous bisphosphonate or denosumab is recommended to manage severe or symptomatic hypercalcemia effectively.[27]
Lymphomas or certain granulomatous diseases like sarcoidosis may activate extrarenal 1α-hydroxylase, the enzyme responsible for converting 25-hydroxyvitamin D to calcitriol. This leads to elevated calcitriol levels and hypercalcemia of malignancy, which should be separated from iatrogenic administration.[28]
Signs & Symptoms
feeling more tired than usual
loss of appetite
loss of concentration or interest
constipation
low mood or increase in irritability
feeling thirsty
passing urine more than usual
dry mouth
nausea and vomiting
drowsiness or confusion
muscle spasms
palpitation or irregular heartbeat
Toxicity
Toxicity
LD50 (oral, rat) = 620 μg/kg; LD50 (intraperitoneal, rat) > 5 mg/kg MSDS.
Monograph
Reference
Introduction
Sildenafil, commonly known as Viagra, is a groundbreaking medication primarily used to treat erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). It represents a pivotal advancement in sexual health and has undergone significant development since its introduction in 1998.
Origins and Approval
Sildenafil was originally developed by Pfizer in the early 1990s as a treatment for angina (chest pain related to heart issues). However, during clinical trials, it was discovered that the drug had a remarkable side effect: it induced erections in male participants, leading to its repurposing for men suffering from erectile dysfunction. The U.S. Food and Drug Administration (FDA) approved Sildenafil as the first oral treatment for ED in 1998, heralding a new era in sexual medicine
History
History of Sildenafil
🔬 Discovery: A Serendipitous Find
Early 1990s: Scientists at Pfizer in the UK were researching a compound, later known as sildenafil citrate, as a treatment for angina pectoris (chest pain due to heart disease).
It worked by dilating blood vessels via the nitric oxide–cGMP pathway, which seemed promising for improving heart blood flow.
😲 Unexpected Effect
During clinical trials, sildenafil didn’t significantly relieve chest pain...
But: Male participants reported unexpected erections!
Pfizer quickly shifted focus from heart disease to erectile dysfunction (ED).
🚀 FDA Approval & Launch
1998: The U.S. Food and Drug Administration (FDA) approved sildenafil for ED under the brand name Viagra.
It became the first oral treatment for ED — and was a game-changer.
Within weeks, it became a cultural phenomenon and a blockbuster drug.
💡 Medical and Cultural Impact
Removed stigma around discussing male sexual health.
Led to a surge in men seeking help for ED.
Inspired jokes, ads, and even political debates — Viagra became more than a medicine; it was a pop culture icon.
💊 Expansion of Use
2005: Approved as Revatio to treat pulmonary arterial hypertension (PAH).
Research into other uses followed (e.g., heart failure, Raynaud’s, altitude sickness).
💼 Generic Availability
2013–2017: Patents expired in various countries.
Multiple pharmaceutical companies began manufacturing generic sildenafil, greatly reducing its cost.
🌐 Today
One of the most widely recognized and prescribed drugs globally.
Still used for both ED and PAH.
Ongoing research explores other vascular and neurological applications.
MOA
Erectile dysfunction: Does not directly cause penile erections but affects the response to sexual stimulation. The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE-5), which is responsible for degradation of cGMP in the corpus cavernosum; when sexual stimulation causes local release of NO, inhibition of PDE-5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum; at recommended doses, it has no effect in the absence of sexual stimulation.
Pulmonary arterial hypertension (PAH): Inhibits phosphodiesterase type 5 (PDE-5) in smooth muscle of pulmonary vasculature where PDE-5 is responsible for the degradation of cyclic guanosine monophosphate (cGMP). Increased cGMP concentration results in pulmonary vasculature relaxation; vasodilation in the pulmonary bed and the systemic circulation (to a lesser degree) may occur.
Examples of Medication Brand Names
VIAGRA (tab)
EREC (tab)
SILDEN (tab)
Nerhasilda (film)
Indications
Approved Indications for Sildenafil
1. Erectile Dysfunction (ED)
Primary Use: Helps men achieve and maintain an erection sufficient for sexual activity.
Mechanism: Enhances the effects of nitric oxide by inhibiting PDE5, allowing increased blood flow to the penis.
Brand Name: Viagra
2. Pulmonary Arterial Hypertension (PAH)
Used to treat: High blood pressure in the arteries of the lungs (WHO Group I PAH).
Improves: Exercise capacity, symptoms, and delays disease progression.
Brand Name: Revatio
Typical dose: Lower and more frequent than in ED (e.g., 20 mg 3 times daily).
⚠️ Off-Label / Investigational Uses (Not officially approved but studied or prescribed in certain situations)
3. Raynaud’s Phenomenon
Helps reduce frequency and severity of vasospastic attacks in people with this condition.
4. Altitude Sickness / High-Altitude Pulmonary Edema (HAPE)
Sildenafil has been used to reduce pulmonary pressure at high altitudes, potentially preventing or managing HAPE.
5. Female Sexual Arousal Disorder (experimental/under research)
Some studies have explored its potential to improve genital blood flow in women, but evidence is mixed.
6. Heart Failure with Preserved Ejection Fraction (HFpEF) (investigational)
Studied for improving exercise tolerance in certain types of heart failure, though not routinely used.
SIDE EFFECTS
Common Side Effects (usually mild and temporary)
Headache
Flushing (redness or warmth in the face, neck, or chest)
Nasal congestion (stuffy nose)
Dizziness
Indigestion (dyspepsia)
Back pain or muscle aches
Visual disturbances
e.g., blurred vision, blue-tinged vision (cyanopsia), sensitivity to light
⚠️ Less Common Side Effects
These are less frequent but can still occur:
Nausea or vomiting
Rash
Mild decrease in blood pressure
Insomnia
Runny nose
Increased heart rate (tachycardia)
Eye irritation or dry eyes
Precautions & Contraindications
Precautions Before Using Sildenafil
Patients should inform their healthcare provider about the following:
🫀 Cardiovascular Health
History of heart disease, heart failure, arrhythmias, stroke, or myocardial infarction (heart attack).
Risk of sexual activity should be assessed in men with significant cardiac conditions.
💊 Medication Use
Concomitant use of nitrates (e.g., nitroglycerin) or nitric oxide donors is dangerous and strictly contraindicated.
Caution with drugs that affect CYP3A4 metabolism (e.g., ketoconazole, ritonavir) due to increased sildenafil levels.
👁️ Eye Conditions
Rare cases of non-arteritic anterior ischemic optic neuropathy (NAION) reported—avoid in patients with a history of NAION or hereditary retinal disorders (like retinitis pigmentosa).
🧠 Neurological Risk
Use cautiously in those with a history of seizures or intracranial hemorrhage.
🩺 Liver or Kidney Impairment
Dose adjustments may be required in hepatic or severe renal impairment.
🔼 Low Blood Pressure (Hypotension)
May cause a drop in blood pressure—caution in those with resting hypotension or on antihypertensive therapy.
❗ Other Considerations:
Priapism risk in patients with anatomical deformation of the penis (e.g., Peyronie’s disease) or predisposition to prolonged erections (e.g., sickle cell anemia, leukemia).
Not approved for use in women or children (except for PAH in some pediatric cases under medical supervision).
🚫 Contraindications
Sildenafil should NOT be used in the following situations:
Concurrent use of nitrates (e.g., for angina) → risk of life-threatening hypotension.
Severe cardiovascular disorders:
Recent heart attack (within 6 months)
Recent stroke
Unstable angina
Severe hypotension (BP <90/50 mmHg)
Severe liver impairment
Hereditary degenerative retinal disorders (e.g., retinitis pigmentosa)
Known hypersensitivity/allergy to sildenafil or any excipients
What HAPPENS AFTER TAKING A VIAGRA ?
WHAT DRUGS SHOULD NOT BE TAKEN WITH VIAGRA ?
Monograph
Reference
Introduction
Flumazenil is a benzodiazepine antagonist typically used in overdose emergencies. The primary FDA-approved clinical uses for flumazenil include reversal agents for benzodiazepine overdose and postoperative sedation from benzodiazepine anesthetics. Flumazenil injection is indicated for a complete or partial reversal of the sedative effects of benzodiazepines in conscious sedation and general anesthesia in adult and pediatric populations. This activity focuses on the indications, mechanism of action, dosing, significant adverse effects, contraindications, monitoring, and toxicity of flumazenil so clinicians can direct patient therapy for optimal outcomes in benzodiazepine reversal. Empowering clinicians with the necessary knowledge and skills to navigate flumazenil therapy is paramount.
MOA
Mechanism of action:
Flumazenil is a benzodiazepine antagonist. It competitively inhibits the activity of benzodiazepine and non-benzodiazepine substances that interact with benzodiazepine receptors site on the GABA/benzodiazepine receptor complex. It can also reverse the binding of benzodiazepines to benzodiazepine receptors.
Intravenous (IV) flumazenil antagonizes sedative effects, impairment of recall, and psychomotor impairment produced by benzodiazepines
Examples of Medication Brand Names
Anexate 0.5mg (Amp)
Flumazenil 0.5 mg(vial)
Romazicon 0.5mg (vial)
Indication
Indication :
Flumazenil is a benzodiazepine antagonist used to:
☆FDA-Approved Uses:
1- Treat benzodiazepine overdose (more effective in single-drug cases).
2- Reverse postoperative benzodiazepine sedation in adults and children.
3- Speed up recovery and discharge after minor procedures.
☆Off-Label Uses:
1- Alcohol withdrawal
2- Baclofen or cannabis toxicity
3- Hepatic encephalopathy
4- Benzodiazepine detox
Also helps reverse respiratory depression and sedation per ASA guidelines.
Side effects
Nervous system:Dizziness (vertigo, ataxia) occurring in approximately 10% of patients; headache and paresthesia (abnormal sensations) are also reported.
Psychiatric: Agitation, anxiety, nervousness, dry mouth, tremor, palpitations, insomnia, dyspnea, hyperventilation, and emotional lability.
Cardiovascular:Cutaneous vasodilation (sweating, flushing, hot flushes); less commonly, cardiac dysrhythmias such as ventricular tachycardia and junctional tachycardia.
Other: Fatigue, malaise, injection site pain, abnormal vision (visual field defects, diplopia), and hiccups.
Serious adverse events, such as convulsions, have occurred, particularly in patients with severe hepatic impairment, those dependent on benzodiazepines, or those who have ingested large doses of other drugs in addition to benzodiazepines.
Precautions & Contraindications
Precautions
Flumazenil provokes panic attacks in patients with a history of panic disorder.
Convulsions may occur in patients with a chronic dependency on benzodiazepines.
Flumazenil may precipitate convulsions or altered cerebral blood flow in patients with a head injury.
Increased risk of seizures exists in epileptic patients on benzodiazepine treatment for a prolonged period.
Caution is advised in patients with drug dependency or alcoholism due to increased frequency of benzodiazepine tolerance and dependence.
Do not use as primary treatment in patients with severe lung disease with respiratory depression secondary to benzodiazepines.
Signs of tricyclic antidepressant overdose or mixed overdoses should not be treated with flumazenil.
According to American Heart Association (AHA) guidelines for cardiac arrest, flumazenil reverses the respiratory depression induced by benzodiazepine poisoning; however, its utilization is constrained by significant risks and contraindications.
Contraindications:
Hypersensitivity to flumazenil or benzodiazepines
Benzodiazepine administration for life-threatening diseases such as control of intracranial pressure or status epilepticus
Signs of tricyclic antidepressant overdose.
Monograph
Reference
Introduction
Desmopressin is a synthetic analog of the hormone vasopressin (antidiuretic hormone - ADH), and it is primarily used to treat conditions related to water balance disorders in the body.
Desmopressin is a hormonal medication used to replace the deficiency of vasopressin, which helps reduce urine output and increase urine concentration. It is commonly used to treat:
Diabetes insipidus, caused by a lack of antidiuretic hormone (ADH).
Nocturnal enuresis (bedwetting) in children.
Certain bleeding disorders, such as von Willebrand disease and mild hemophilia A, as it stimulates the release of von Willebrand factor and factor VIII.
Desmopressin is available in several pharmaceutical forms, including tablets, nasal spray, and injections. It should be used with caution to avoid hyponatremia (low sodium levels in the blood), especially in children and the elderly.
Desmopressin (DDAVP) Mechanism of Action (MOA)
Desmopressin is a synthetic analog of the natural hormone vasopressin (antidiuretic hormone, ADH). Its primary actions are:
1. Antidiuretic Effect (Kidneys):
- Binds to V2 receptors in the collecting ducts of the kidneys.
- Increases water reabsorption by promoting the insertion of aquaporin-2 channels into the tubular membrane.
- Reduces urine output (antidiuresis) and increases urine concentration.
2. Hemostatic Effect (Blood Clotting):
- At higher doses, it stimulates V2 receptors on vascular endothelium, increasing the release of **von Willebrand factor (vWF) and factor VIII from storage sites.
- This helps in improving clotting in conditions like hemophilia and Willebrand disease**.
Examples of Medication Brand Names
Desmoliv-2 (tab)
DDAVP (tab)
Octoconval (tab)
minirin (nasal spray)
Indications
1. Central Diabetes Insipidus
– To manage excessive urination and thirst caused by a deficiency of antidiuretic hormone (ADH).
2. Nocturnal Enuresis (Bedwetting)
– For children aged 6 years and older who have difficulty controlling nighttime urination.
3. Nocturia in Adults
– To reduce nighttime urination in adults with nocturia due to nocturnal polyuria.
4. Bleeding Disorders
– Used in mild Hemophilia A and von Willebrand disease (Type 1) to increase levels of factor VIII and von Willebrand factor.
5. Surgical or Trauma-Related Bleeding
– In patients with mild bleeding disorders to prevent or control bleeding.
SIDE EFFECTS
Side Effects of Desmopressin Common:
Headache
Nausea
Abdominal pain
Nasal congestion or runny nose (especially with the nasal spray)
Fluid retention
2. Serious (but rare):
Hyponatremia (low blood sodium):
One of the most serious complications, which may lead to:
Severe headache
Nausea and vomiting
Seizures
Confusion or coma
3. Less common side effects:
High or low blood pressure
Dizziness
Skin rash or allergic reaction
Weight gain (due to fluid retention)
Precautions & Contraindications
Precautions:
Monitor blood sodium levels to avoid hyponatremia.
Avoid excessive fluid intake during treatment.
Use with caution in:
Elderly patients
Young children
Patients with heart or kidney diseases
Cases of high blood pressure
Careful monitoring is required during long-term or high-dose use.
-Contraindications:
Hypersensitivity to Desmopressin or any of its components.
Current or history of hyponatremia.
Severe renal impairment.
Serious heart conditions, such as congestive heart failure.
Nephrotic syndrome.
Nocturnal Enuresis
1. Nocturnal Enuresis (Bedwetting):
Studies have shown Desmopressin's effectiveness in reducing nighttime bedwetting in children, with significant improvement, especially in studies conducted in Egypt.
2. Nocturia in Adults:
Studies have demonstrated Desmopressin's effectiveness in reducing the number of nighttime urinations in women and patients suffering from excessive nighttime urination.
3. Bleeding Disorders:
Studies have shown that Desmopressin is effective in reducing bleeding and improving clotting factor levels in patients with Hemophilia A and certain types of von Willebrand disease.
4. Side Effects and Safety:
Studies confirm that Desmopressin is safe and effective in improving nighttime urination, with a need to monitor for side effects such as fluid retention.
Monograph
Reference
By :Ahmed Afifi Abdelhaled
INTRODUCTION
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue filgrastim, designed to reduce infection risk by boosting neutrophil production. Approved by the FDA in 2002 under the brand name Neulasta, it is primarily used to prevent febrile neutropenia in patients undergoing myelosuppressive chemotherapy for non-myeloid malignancies. By binding to G-CSF receptors, it activates pathways that enhance neutrophil proliferation, maturation, and function. Its PEGylation extends its half-life to 15–80 hours, allowing single-dose administration per chemotherapy cycle instead of daily injections required for filgrastim. Biosimilars like Fulphila and Udenyca offer equivalent efficacy with the same dosing regimen. Pegfilgrastim is also indicated for hematopoietic subsyndrome of acute radiation syndrome
MECHANISM OF ACTION
Pegfilgrastim is a long-acting form of filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF), designed to stimulate the production and maturation of neutrophils, which are essential white blood cells for fighting infections. After administration, pegfilgrastim binds to G-CSF receptors located on the surface of neutrophil precursor cells and mature neutrophils in the bone marrow. This receptor binding activates intracellular signaling pathways such as JAK/STAT, PI3K/AKT, and MAPK/ERK, which promote the proliferation, differentiation, and survival of neutrophil progenitors, leading to an increased number of functional neutrophils in the bloodstream. The PEGylation of pegfilgrastim extends its half-life by reducing renal clearance, allowing sustained stimulation of neutrophil recovery during periods of chemotherapy-induced neutropenia. Additionally, pegfilgrastim clearance is regulated by neutrophil levels themselves: as neutrophil counts rise, these cells bind and internalize pegfilgrastim, promoting its degradation and reducing circulating drug levels. This feedback mechanism ensures that pegfilgrastim remains active when neutrophil counts are low and decreases as normal neutrophil levels are restored, effectively reducing the risk of infection in patients undergoing myelosuppressive chemotherapy.
EXAMPLES
INDICATION
Pegfilgrastim is primarily indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies who are receiving myelosuppressive anti-cancer drugs associated with a clinically significant risk of febrile neutropenia. It is also approved to increase survival in patients acutely exposed to myelosuppressive doses of radiation, specifically for the Hematopoietic Subsyndrome of Acute Radiation Syndrome. Pegfilgrastim is not indicated for mobilizing peripheral blood progenitor cells for hematopoietic stem cell transplantation
SIDE EFFECTS
Pegfilgrastim commonly causes side effects such as bone pain, pain in the arms or legs, and musculoskeletal discomfort. Other frequent side effects include fever, chills, cough, sore throat, and mouth sores. Some patients may experience gastrointestinal symptoms like belching, constipation, diarrhea, heartburn, and changes in taste. More serious but less common side effects include inflammation of the aorta (aortitis), capillary leak syndrome, allergic reactions (such as swelling of the face, throat, or mouth, hives, rash, and difficulty breathing), and symptoms indicating possible blood disorders like unusual bleeding, bruising, or fatigue. Rare side effects can involve chest pain, trouble breathing, bluish skin, and injection site reactions such as redness, swelling, or pain. Patients should seek immediate medical attention if they experience severe symptoms such as difficulty breathing, chest pain, or signs of an allergic reaction
PRECAUTIONS & CONTRAINDICATIONS
Pegfilgrastim is contraindicated in patients with a known hypersensitivity to pegfilgrastim, filgrastim, or any components derived from E. coli used in its production. It should also be avoided in individuals with sickle cell disease or sickle cell trait due to the increased risk of severe sickle cell crises. Additionally, pegfilgrastim is not approved for use in mobilizing peripheral blood progenitor cells for hematopoietic stem cell transplantation. Common adverse effects include bone pain, injection site reactions, and in rare cases, serious complications such as splenic rupture, acute respiratory distress syndrome (ARDS), and severe allergic reactions. Patients with latex allergies should exercise caution with certain formulations that have latex-containing needle caps. Regarding physical percussion or percussion therapy, there are no specific contraindications or warnings associated with pegfilgrastim use. Overall, patients receiving pegfilgrastim should be closely monitored for signs of hypersensitivity, splenic enlargement or rupture, and other adverse effects, but no restrictions related to percussion therapy have been documented.
MONOGRAPH
REFERENCES
1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9bfc4d3e-6120-7fec-f1d6-
0b3743752034
2. https://pubmed.ncbi.nlm.nih.gov/21456630/
3. https://www.drugs.com/search.php?searchterm=pegfilgrastim&a=1
4. https://www.rxlist.com/drug-interaction-checker.htm
introduction
N-acetylcysteine, also known as Acetylcysteine and NAC, is a medication that is used to treat paracetamol (acetaminophen) overdose and to loosen thick mucus in individuals with chronic bronchopulmonary disorders, such as pneumonia and bronchitis. It has been used to treat lactobezoar in infants
MOA
1. Antioxidant:
NAC supplies cysteine to boost glutathione (GSH) production, which protects cells by neutralizing harmful reactive oxygen species (ROS).
2. Mucolytic:
It breaks disulfide bonds in mucus, reducing its thickness and making it easier to clear from the lungs.
3. Antidote for Paracetamol Overdose:
NAC restores glutathione levels, helping detoxify the harmful metabolite (NAPQI) and preventing liver damage.
4. Anti-inflammatory:
It reduces inflammation by inhibiting certain cellular signaling pathways like NF-κB.
Examples of Medication Brand Names
FLUIMUCIL
ACENEWRAX
BRAND CYSTEINE
Sure! Here's a summary of the indications for N-acetylcysteine (NAC):
1. Acetaminophen (Paracetamol) Overdose
Primary indication
NAC replenishes glutathione, allowing the body to detoxify the harmful metabolite (NAPQI) of acetaminophen.
Most effective if given within 8–10 hours of overdose, but can still be beneficial later.
2. Mucolytic Agent (Respiratory Conditions)
Breaks disulfide bonds in mucus, reducing viscosity
Used in chronic bronchitis, cystic fibrosis, and other respiratory diseases with thick mucus
Available as inhalation or oral solution
3. Prevention of Contrast-Induced Nephropathy
Used off-label (controversial benefit)
Administered before and after contrast exposure in high-risk patients (e.g., with renal impairment)
4. Chronic Obstructive Pulmonary Disease (COPD)
Acts as an antioxidant and mucolytic to reduce exacerbations (used more in some countries like Europe)
5. Psychiatric and Neurological Uses (Off-label)
Investigated in conditions like:
Obsessive-Compulsive Disorder (OCD)
Addiction (e.g., cannabis, cocaine, nicotine)
Schizophrenia
Bipolar disorder
Works as a glutamate modulator and antioxidant
6. Liver Protection in Non-Acetaminophen Liver Injury (Off-label)
Sometimes used in acute liver failure due to other causes (e.g., viral hepatitis), especially in early stages
Side Effects
1. Nausea
2. Vomiting
3. Diarrhea
4. Abdominal pain
5. Unpleasant sulfur-like taste or smell
Less Common / Serious Side Effects:
1. Allergic reactions (rash, itching, swelling)
2. Bronchospasm (especially in asthma patients)
3. Hypotension (low blood pressure – mainly with IV use)
4. Anaphylactoid reactions (flushing, chest tightness, shortness of breath – usually with IV)
Precautions & Contraindications
Precautions:
1. Asthma: Risk of bronchospasm in asthma patients.
2. Pregnancy/Breastfeeding: Use only if necessary and under supervision.
3. Kidney Issues: Caution in kidney disease patients.
4. Gastrointestinal Symptoms: May cause nausea, vomiting, or diarrhea.
5. Surgery: May need to be stopped before surgery due to effects on blood pressure and immune response.
Contraindications:
1. Allergy to NAC: Avoid if hypersensitive.
2. Severe Respiratory Conditions: Risk of severe bronchospasm in severe asthma.
3. Severe Liver/Kidney Failure: Avoid in these conditions.
Monograph
Reference
Introduction
Zoledronic acid is a bisphosphonate medication used to prevent bone loss. It works by inhibiting bone resorption, making bones stronger and reducing the risk of fractures.
MOA
2. Mechanism of Action
Zoledronic acid inhibits the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway. This disrupts the function and survival of osteoclasts (bone-resorbing cells), leading to reduced bone resorption and increased bone density.
Examples of Medication Brand Names
Indications
Osteoporosis in postmenopausal women and men
Hypercalcemia of malignancy
Bone metastases from solid tumors
Multiple myeloma
Paget’s disease of bone
Side effect
gitation
black, tarry stools
blurred vision
chest pain
chills
coma
confusion
convulsions
cough
depression
difficult or labored breathing
Serious:
Hypocalcemia
renal impairment,
osteonecrosis of the jaw
atypical femur fractures
feeling of constant movement of self or surroundings
muscle cramps in the hands, arms, feet, legs, or face
muscle spasms
neck pain
pounding in the ears
rapid breathing
sensation of spinning
slow or fast heartbeat
sunken eyes
tingling of the hands or feet
tremor
Precautions & Contraindications
6. Precautions & Contraindications
Precautions:
Monitor kidney function before and during treatment
Ensure adequate hydration
Check calcium and vitamin D levels
Contraindications:
Hypocalcemia
Severe renal impairment (CrCl < 35 mL/min)
Known hypersensitivity to zoledronic acid or other bisphosphonates
Monograph
Reference
BY: Asmaa Reda Abo Alwafa
Introduction
Octreotide is a synthetic analog of somatostatin, a naturally occurring hormone that inhibits the release of several other hormones and substances in the body. It is most commonly used to manage symptoms of hormone-secreting tumors and to treat conditions like acromegaly, carcinoid syndrome, and VIPomas (vasoactive intestinal peptide tumors).
Brand names include: Sandostatin, Sandostatin LAR Depot.
It mimics somatostatin, but has a longer half-life, allowing it to be more effective in clinical use.
Works by reducing the secretion of serotonin, growth hormone, insulin, glucagon, and other peptides.
Available in both short-acting (injection multiple times daily) and long-acting (monthly injection) forms.
MOA
Octreotide is a somatostatin analog that binds to somatostatin receptors (SSTRs) — mainly SSTR2 and SSTR5 — on various cells, mimicking the natural effects of somatostatin.
🔹 Once bound to these receptors, octreotide:
Inhibits secretion of several hormones and peptides, including:
Growth hormone (GH)
Insulin
Glucagon
Vasoactive intestinal peptide (VIP)
Serotonin
Gastrin
Pancreatic polypeptide
Reduces gastrointestinal secretions and motility
Slows down gastric emptying and intestinal transit
Inhibits splanchnic (intestinal) blood flow
Helpful in reducing bleeding from varices in liver disease
Suppresses growth hormone and IGF-1 in conditions like acromegaly
🧠 Clinical Effects:
Decreases hormone-related symptoms (e.g., flushing, diarrhea)
Reduces tumor secretions in neuroendocrine tumors
Lowers portal pressure in cirrhotic patients with variceal bleeding
Examples of Medication Brand Names
Sandostatin (Novartis)
Sandostatin LAR Depot (Long-Acting Release Formulation)
Mycapssa (Oral Formulation)
Bynfezia Pen (Pre-Filled Pen for Injection)
Indications
Acromegaly
Neuroendocrine tumors (e.g., carcinoid, VIPoma)
Severe diarrhea (e.g., due to tumors or HIV)
Esophageal variceal bleeding
Pancreatic fistulas/postoperative support
side effects
Common Side Effects:
Gastrointestinal:
Nausea
Vomiting
Abdominal pain
Bloating
Diarrhea or constipation
Flatulence
Injection site reactions:
Pain
Redness
Swelling
Gallbladder-related:
Gallstones or biliary sludge (due to reduced gallbladder motility)
🔹 Endocrine/Metabolic:
Hyperglycemia or hypoglycemia
Because octreotide affects insulin and glucagon secretion
Hypothyroidism (rare, especially with long-term use)
🔹 Cardiovascular:
Bradycardia (slow heart rate)
Conduction abnormalities on ECG (e.g., prolonged QT interval in rare cases)
🔹 Other Possible Effects:
Headache
Dizziness
Fatigue
Hair loss (rare)
Pancreatitis
Severe bradycardia or heart block
Allergic reactions (e.g., rash, anaphylaxis — very rare)
Precautions & Contraindications
Precautions:
1. Gallbladder Issues:
May cause gallstones or biliary sludge with long-term use.
2. Glucose Metabolism:
Can cause hypo- or hyperglycemia due to effects on insulin and glucagon secretion. Monitor blood sugar levels closely.
3. Cardiac Effects:
May lead to bradycardia, conduction abnormalities, or QT prolongation. Use cautiously in patients with cardiac disease.
4. Thyroid Function:
Can decrease TSH secretion, possibly leading to hypothyroidism.
5. Renal Impairment:
Dosage adjustment may be needed, especially for long-acting forms.
6. Injection Site Reactions:
Pain, swelling, or nodules can occur with subcutaneous injections.
Contraindications:
1. Hypersensitivity to octreotide or any of its components.
2. Caution in pregnancy and lactation – safety not fully established.
Monograph
Reference
Introduction
Dimercaprol, also known as British Anti-Lewisite (BAL), is a chelating agent developed during World War II at Oxford University as an antidote to the arsenic-based chemical warfare agent, Lewisite. It has been used clinically since 1949 to treat heavy metal poisoning, including arsenic, mercury, lead, and gold.
Mechanism of Action
Dimercaprol contains sulfhydryl (-SH) groups that bind to heavy metal ions, forming stable, non-toxic complexes that are excreted in the urine. This process prevents the metals from interacting with critical enzymes in the body.
Illustration: A visual showing how dimercaprol binds to metal ions to detoxify them.
Examples
Indication
Dimercaprol is used in the treatment of:
Acute arsenic poisoning
Mercury and lead poisoning
Gold poisoning
Wilson’s disease (alternative copper chelator)
Radiation exposure (e.g., mercury or polonium-210
Side Effects
Common:
Nausea and vomiting
Headache
Pain at the injection site
Hypertension
Tachycardia
Serious:
Kidney toxicity
Liver damage
Allergic reactions
Anemia
Fluid retention
Precautions And Contraindications
Do not combine with iron or iron-containing multivitamins – increases toxicity.
Contraindicated in cadmium and selenium poisoning – may form toxic complexes.
Use cautiously in patients with kidney or liver impairment.
Monograph
References
https://accesspharmacy.mhmedical.com/content.aspx?bookid=2569§ionid=210263297 :]1[-
https://en.wikipedia.org/wiki/Dimercaprol :]2[-
https://www.inchem.org/documents/pims/pharm/dimercap.htm :]3[-
/https://www.ncbi.nlm.nih.gov/books/NBK548426 :]4[-
https://go.drugbank.com/drugs/DB06782 :]5[-
https://www.mims.com/malaysia/drug/info/dimercaprol?mtype=generic :]6[-
/https://www.ncbi.nlm.nih.gov/books/NBK549804 :]7[
Introduction
Erythropoietin is a natural hormone mainly produced by the kidneys. It plays a key role in stimulating the bone marrow to produce red blood cells in response to low oxygen levels in the blood. As a medication, erythropoietin is used to treat anemia, especially in patients with chronic kidney disease or those undergoing chemotherapy.
MOA
Mechanism of Action of Erythropoietin (EPO):
1. Low oxygen (hypoxia) → kidneys sense the drop.
2. Kidneys release EPO into the blood.
3. EPO travels to bone marrow.
4. EPO binds to receptors on red blood cell precursors.
5. Stimulates red blood cell production.
6. More RBCs → more oxygen → EPO levels decrease (feedback control)
Examples of Medication Brand Names
Indication
1. Anemia in Chronic Kidney Disease (CKD)
Especially in patients on dialysis or pre-dialysis
EPO is used to reduce the need for blood transfusions
2. Anemia due to Chemotherapy
For cancer patients receiving chemotherapy who develop anemia
3. Anemia in HIV Patients
Particularly in those treated with zidovudine (AZT)
4. Before Surgery (Preoperative Use)
To reduce the need for blood transfusions in patients with anemia undergoing elective surgery
5. Anemia in Premature Infants (off-label use in some regions)
To stimulate red cell production in neonates
Side Effects
Headache
Joint or muscle pain
Nausea or vomiting
Fever
Injection site reactions (pain, redness, swelling)
Cough or respiratory symptoms
Serious Side Effects:
High blood pressure (hypertension)
Especially in patients with kidney disease
Blood clots (thrombosis)
Increased risk of stroke, deep vein thrombosis (DVT), or heart attack
Pure red cell aplasia (PRCA) (rare)
A condition where the body stops producing red blood cells due to antibody development against EPO
Seizures
Mostly in patients with rapid rise in hemoglobin
Allergic reactions
Rash, itching, or rare anaphylaxis
Warnings:
Should not be used to raise hemoglobin above 12 g/dL due to risk of cardiovascular events.
Must be used under close medical supervision and with regular hemoglobin monitoring.
Precautions & Contraindications
Precautions:
1. Monitor Hemoglobin Levels Closely
Target hemoglobin should not exceed 12 g/dL to avoid risk of stroke or heart attack.
2. Control Blood Pressure Before Starting Treatment
EPO can worsen hypertension; BP must be well-managed.
3. Iron Status Monitoring
Adequate iron levels are required for EPO to be effective; iron supplements may be needed.
4. Increased Risk of Tumor Progression
In some cancer patients, EPO might shorten survival or increase tumor growth—use with caution.
5. Seizure Risk
Especially in patients with kidney disease or those with rapid rise in hemoglobin.
6. Thromboembolic Events
Monitor patients at risk (e.g., post-surgery, immobilized patients).
7. Use in Pregnant or Breastfeeding Women
Use only if clearly needed; safety data is limited.
Contraindications:
1. Uncontrolled Hypertension
Absolute contraindication due to risk of hypertensive crisis.
2. Hypersensitivity to Erythropoietin or its Components
Includes allergy to human albumin or polysorbate.
3. Pure Red Cell Aplasia (PRCA) After EPO Treatment
Especially antibody-mediated cases—do not use again.
4. Functional Iron Deficiency or Uncorrected Deficiencies
Monograph
Refrences
By: Ahmed reda mobarak
Introduction
Filgrastim is a medication that belongs to a class of drugs known as granulocyte colony-stimulating factors (G-CSFs). It is primarily used to stimulate the bone marrow to produce more white blood cells, particularly neutrophils. This makes it especially useful in treating or preventing neutropenia—a condition characterized by a low neutrophil count—which can result from chemotherapy, bone marrow transplantation, certain cancers, or congenital disorders.
Filgrastim is a recombinant form of the natural G-CSF protein produced using genetic engineering techniques. It is administered via subcutaneous or intravenous injection and helps reduce the duration and severity of neutropenia, thereby lowering the risk of infections in immunocompromised patients.
MOA
Filgrastim is a recombinant human granulocyte colony-stimulating factor (rhG-CSF) that mimics the action of the natural G-CSF produced by the body. Its primary role is to stimulate the proliferation, differentiation, and activation of neutrophil precursors in the bone marrow, thereby increasing the number of functional neutrophils in the blood.
Step-by-Step Mechanism:
1. Binding to G-CSF Receptors (G-CSFR):
Filgrastim binds to specific G-CSF receptors on hematopoietic stem and progenitor cells in the bone marrow.
2. Signal Transduction Activation:
Binding activates intracellular signaling pathways such as:
JAK/STAT pathway
PI3K/AKT pathway
MAPK pathway
These pathways promote gene transcription involved in survival, proliferation, and maturation of neutrophil precursors.
3. Proliferation and Differentiation:
This leads to an increased production of neutrophils from the myeloid lineage in the bone marrow
4. Enhanced Neutrophil Function:
Filgrastim also improves the migratory and phagocytic capabilities of mature neutrophils, boosting the body's immune response.
5. Reduced Duration of Neutropenia:
By accelerating neutrophil recovery, Filgrastim shortens the period of neutropenia after chemotherapy or bone marrow suppression, thereby reducing the risk of infections.
Examples of Medication brand name ( with Images ) .
Route of administration: Subcutaneous injection & intravenous injection
Route of administration: Subcutaneous injection & intravenous injection
Route of administration: Subcutaneous injection & intravenous injection
Indication
Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF). It stimulates the bone marrow to produce more neutrophils, which are essential white blood cells that help fight infections. It’s mainly used in conditions where the body’s ability to produce neutrophils is reduced or impaired.
Clinical indications of Filgrastim:
Filgrastim is commonly used in cancer patients receiving myelosuppressive chemotherapy to reduce the risk of infection by decreasing the duration of chemotherapy-induced neutropenia. It is not used in patients with myeloid leukemia, as it may stimulate malignant cells.
It is also indicated in patients undergoing bone marrow transplantation, to accelerate neutrophil recovery after the procedure.
In patients with severe chronic neutropenia—such as congenital, cyclic, or idiopathic neutropenia—Filgrastim is used to maintain adequate neutrophil counts and prevent infections.
Another indication is for the mobilization of peripheral blood progenitor cells (PBPCs) into the bloodstream, where they can be collected for stem cell transplantation.
Filgrastim is also approved for use in patients exposed to myelosuppressive levels of radiation, such as in a nuclear event, to treat acute radiation syndrome by boosting neutrophil counts.
Side Effects
Common Side Effects:
Bone pain: This is the most common side effect, typically felt in the lower back, hips, or limbs. It happens as the bone marrow increases its production of white blood cells.
Muscle or joint pain: Some people may experience discomfort in their muscles or joints.
Headache: Mild to moderate headaches are frequently reported.
Fatigue or weakness: Patients may feel unusually tired or weak during treatment.
Fever: A mild fever can develop, especially if the body is reacting to the medication.
Nausea: Some may feel nauseous, particularly at the start of treatment.
Skin rash or itching: A mild rash or itching may occur as the body adjusts to the medication.
Injection site reactions: Redness, swelling, or pain at the site of the injection is common and typically temporary.
---
Less Common but Serious Side Effects:
Splenomegaly (enlarged spleen): Can cause pain in the left upper abdomen or shoulder tip. In rare cases, the spleen can rupture, which is a medical emergency.
Allergic reactions: Swelling, trouble breathing, rash, or anaphylaxis (rare but serious).
Acute Respiratory Distress Syndrome (ARDS): Severe shortness of breath and lung problems, usually in very ill patients.
Capillary Leak Syndrome: A rare condition where fluids leak from blood vessels, causing low blood pressure, swelling, and risk of organ failure.
Myelodysplastic syndrome or leukemia: In patients with certain risk factors or previous cancers, there may be a small increased risk.
Precautions & Contraindications
Precautions:
1.Monitor white blood cell count: High doses may lead to excessive leukocytosis (too many white blood cells), increasing the risk of complications like splenic rupture or respiratory problems. Regular blood tests are essential.
2.Risk of splenomegaly or splenic rupture: Enlargement of the spleen may occur, sometimes leading to rupture. Patients should be advised to report pain in the left upper abdomen or shoulder.
3.Respiratory symptoms: Monitor for signs of acute respiratory distress syndrome (ARDS), especially in cancer or transplant patients. Sudden shortness of breath or lung inflammation can occur.
4.Capillary leak syndrome: A rare but serious condition where fluids leak out of blood vessels, causing swelling, low blood pressure, and organ dysfunction. Requires urgent medical attention.
5.Allergic reactions: Hypersensitivity, including anaphylaxis, can occur. Filgrastim should be permanently discontinued if a serious allergic reaction happens.
6.Sickle cell disease: Use with caution, as Filgrastim may trigger sickle cell crises in these patients.
7.Cancer patients: Should not be used to increase chemotherapy doses beyond recommended regimens. Also, use cautiously in patients with myeloid malignancies due to risk of stimulating cancer cells.
---
Contraindications:
1.Known hypersensitivity to filgrastim or any of its components, including E. coli–derived proteins (since it's produced using recombinant DNA technology from E. coli).
2.Patients with myeloid malignancies (like chronic myeloid leukemia or myelodysplastic syndrome) should generally avoid Filgrastim unless clearly indicated, as it may stimulate malignant cells.
Drug-Drug interactions
Myelosuppressive chemotherapy or radiotherapy:
Filgrastim should not be given 24 hours before or within 24 hours after chemotherapy or radiation. Combining them can worsen neutropenia and increase toxicity.
Reason: Filgrastim stimulates rapidly dividing cells in the bone marrow, which may be damaged by chemo/radiation.
Lithium:
Lithium can increase the release of neutrophils from the bone marrow. When used with filgrastim, there may be an additive effect, causing elevated white blood cell counts (leukocytosis).
Requires monitoring of blood counts.
Other colony-stimulating factors (e.g., pegfilgrastim, sargramostim):
Should not be used together due to overlapping mechanisms and risk of excessive white blood cell production.
Immunosuppressants or corticosteroids:
May alter the immune response, but no well-established direct interaction. Caution and monitoring may be needed depending on the clinical scenario.
Monograph
Refrences
https://pubmed.ncbi.nlm.nih.gov/7524319/
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103353s5204lbl.pdf
https://www.drugs.com/disease-interactions/filgrastim.html
https://go.drugbank.com/drugs/DB00099
https://www.neupogenhcp.com/filgrastim-mechanism-of-action?utm_source=perplexity
https://www.webmd.com/drugs/2/drug-7729/filgrastim/details?utm_source=perplexity
(Alendronate)
Introduction
Alendronate is a medication belonging to the bisphosphonate class, primarily used to treat and prevent osteoporosis—a condition characterized by weakened bones that are more prone to fractures. It is also effective in managing Paget’s disease of bone, a chronic disorder that causes abnormal bone remodeling, leading to enlarged and misshapen bones. Since its introduction, alendronate has become one of the most commonly prescribed drugs for bone health due to its proven ability to increase bone density and reduce fracture risk.
Mechanism Of Action
Alendronate works by targeting the cells responsible for bone resorption called osteoclasts. Normally, osteoclasts break down old or damaged bone tissue, a process balanced by osteoblasts that build new bone. In osteoporosis, this balance is disrupted, with bone resorption outpacing bone formation, leading to fragile bones.
Examples
Indication
Alendronate is prescribed for several bone-related conditions, including:
Postmenopausal osteoporosis: To reduce the risk of vertebral and hip fractures in women after menopause.
Osteoporosis in men: To increase bone density and reduce fracture risk.
Glucocorticoid-induced osteoporosis: For patients taking corticosteroids long-term, which can weaken bones.
Paget’s disease of bone: To regulate abnormal bone remodeling and reduce bone pain.
Side Effects
While alendronate is generally well tolerated, some patients experience side effects:
Common Side Effects:
Gastrointestinal discomfort such as heartburn, acid reflux, nausea, and abdominal pain
Esophageal irritation or ulcers, especially if not taken correctly
Muscle, joint, or bone pain, which can sometimes be severe
Rare but Serious Side Effects:
Osteonecrosis of the jaw (ONJ): A rare condition involving delayed healing and bone death in the jaw, more common in cancer patients receiving high doses of bisphosphonates.
Atypical femur fractures: Uncommon fractures in the thigh bone that may occur after prolonged use.
Hypocalcemia (low blood calcium), especially if calcium or vitamin D intake is inadequate.
Precautions&contraindication
To ensure safe and effective use of alendronate, certain precautions must be followed:
Administration Instructions:
Take alendronate first thing in the morning on an empty stomach with a full glass (6-8 oz) of plain water.
Remain upright (sitting or standing) for at least 30 minutes after taking the medication to prevent esophageal irritation or ulcers.
Avoid eating, drinking (other than water), or taking other medications for at least 30 minutes post-dose.
Contraindications:
Known hypersensitivity to alendronate or other bisphosphonates
Esophageal abnormalities that delay emptying (e.g., strictures or achalasia)
Inability to remain upright for at least 30 minutes after taking the drug
Hypocalcemia (must be corrected before starting treatment)
MONOGRAPH
References
[1] Medicines for osteoporosis: MedlinePlus Medical Encyclopedia https://medlineplus.gov/ency/patientinstructions/000502.htm
[2] Label: ALENDRONATE SODIUM tablet - DailyMed https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4323d3aa-cbb0-41e2-aba7-7a94a0516993
3] Alendronate (oral route) - Mayo Clinic https://www.mayoclinic.org/drugs-supplements/alendronate-oral-route/description/drg-20061571
[4] Alendronate or Alendronic acid for Osteoporosis - MyOsteoTeam https://www.myosteoteam.com/treatments/alendronate-or-alendronic-acid
[5] Alendronate Drug Information - Indications, Dosage, Side Effects and Precautions https://www.medindia.net/doctors/drug_information/alendronate.htm
[6] Alendronate | Side Effects, Dosage, Uses & More https://www.healthline.com/health/drugs/alendronate-oral-tablet
[7] Alendronate: MedlinePlus Drug Information https://medlineplus.gov/druginfo/meds/a601011.html
[8] Alendronate: Side Effects, Uses, Dosage, Interactions, Warnings https://www.rxlist.com/alendronate/generic-drug.htm
Introduction
Botulinum toxin, or botulinum neurotoxin (commonly called botox), is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes. Botulinum toxin is an acetylcholine release inhibitor and a neuromuscular blocking agent
MOA
Botulinum toxin acts by binding presynaptically to high-affinity recognition sites on the cholinergic nerve terminals and decreasing the release of acetylcholine, causing a neuromuscular blocking effect. This mechanism laid the foundation for the development of the toxin as a therapeutic tool.
Recovery occurs through proximal axonal sprouting and muscle re-innervation by formation of a new neuromuscular junction. De Paiva and colleagues suggest that eventually the original neuromuscular junction regenerates.
BoNT-A and BoNT-E cleave synaptosome-associated protein (SNAP-25), a presynaptic membrane protein required for fusion of neurotransmitter-containing vesicles.
BoNT-B, BoNT-D, and BoNT-F cleave a vesicle-associated membrane protein (VAMP), also known as synaptobrevin.
BoNT-C acts by cleaving syntaxin, a target membrane protein.
Examples of Medication Brand Names
Jeuveau
DAXXIFY
DYSPORT
XEOMIN
Indication
Cosmetic: Smoothing facial wrinkles and lines (e.g., glabellar lines, crow’s feet, forehead lines).
Neurological/Muscular Disorders:
Focal dystonias (e.g., cervical dystonia, blepharospasm, oromandibular dystonia).
Spasticity due to cerebral palsy, stroke, spinal cord injury, or multiple sclerosis.
Strabismus (misalignment of the eyes).
Hemifacial spasm, tremors, and other movement disorders.
Pain and Headache:
Chronic migraine prevention (≥15 headache days/month).
Autonomic Disorders:
Hyperhidrosis (excessive sweating), especially axillary.
Sialorrhea (excessive drooling), hyperlacrimation, and some allergy symptoms.
Urological/Gastrointestinal:
Overactive bladder and urinary incontinence, especially when unresponsive to anticholinergics.
Neurogenic detrusor overactivity.
Achalasia and certain gastrointestinal sphincter dysfunctions
Side Effects
Common Side Effects:
Pain, swelling, bruising, or redness at the injection site
Flu-like symptoms
Headache
Neck pain
Dry mouth
Tiredness
Eye problems such as double vision, blurred vision, drooping eyelids, or dry eyes
Drooping eyebrows
Serious Side Effects (Seek immediate medical attention):
Spread of toxin effects, which can cause botulism-like symptoms such as loss of strength and muscle weakness all over the body, double or blurred vision, drooping eyelids, hoarseness or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing or swallowing
Allergic reactions, which can manifest as breathing problems or wheezing, racing heart, fever, swollen lymph nodes, swelling of the face/lips/mouth/tongue/throat, trouble swallowing or throat tightness, itching/skin rash/hives, nausea/vomiting, dizziness, stomach cramps, or joint pain
Breathing, swallowing, or speaking problems, which can occur hours, days, or weeks after injection due to muscle weakness
Eye surface problems, such as eye dryness or irritation, which can lead to corneal ulcers, especially in those with certain nerve disorders
Eye bleeding, which can affect blood flow to the retina and cause vision problems
Dysphagia (difficulty swallowing)
Muscle weakness
The risk of serious side effects is higher when botulinum toxin is used therapeutically rather than cosmetically, as therapeutic uses often involve larger doses. If you experience any concerning side effects after receiving botulinum toxin injections, contact your healthcare provider immediately
Precautions & Contraindications
Precautions for Botulinum Toxin Use
Qualified Provider: Ensure injections are administered by a licensed and trained medical professional to avoid overdose or improper injection, which can cause iatrogenic botulism.
Avoid Touching Treated Area: Do not rub, massage, or touch the injection site for at least 24 hours to prevent spreading the toxin beyond the target muscle.
Post-Injection Positioning: Sit upright for at least 4 hours after injection; avoid lying down or bending over to reduce toxin migration and bruising risk.
Avoid Alcohol and Blood Thinners: Refrain from alcohol consumption 24 hours before and after injection, as it increases bruising risk. Inform your doctor about blood thinners or medications that may increase bleeding.
Absolute Contraindications
Pregnancy and breastfeeding: Safety not established; use is not recommended.
Allergy or hypersensitivity: Known allergy to botulinum toxin type A or any formulation components such as human albumin.
Active infection or skin conditions: Infection, rash, or inflammatory skin disease at the injection site increases risk of complications.
Neuromuscular disorders: Conditions like myasthenia gravis, Eaton-Lambert syndrome, ALS, or other muscle weakness disorders increase risk of serious adverse effects such as respiratory difficulties.
Hypersensitivity to other neurotoxins: Cross-reactivity may pose risks.
Relative Contraindications (require caution)
Certain medications: Aminoglycoside antibiotics, muscle relaxants, anticoagulants, and NSAIDs may enhance botulinum toxin effects or increase bleeding risk.
Compromised immune system or history of antibody formation: May reduce efficacy or increase adverse effects.
Urinary tract infection or inability to empty bladder: Relevant for bladder-related indications.
Patients with these contraindications should avoid or delay treatment, and practitioners should carefully evaluate risks before proceeding.
Monograph
Refrences
Rasburicase
Rasburicase is a recombinant form of the enzyme urate oxidase, originally derived from the fungus Aspergillus flavus. It is used primarily in the prevention and treatment of hyperuricemia associated with tumor lysis syndrome (TLS) in pediatric and adult patients with hematologic malignancies such as leukemia and lymphoma. Tumor lysis syndrome occurs when cancer cells break down rapidly, releasing large amounts of uric acid into the bloodstream, which can lead to acute kidney injury.
Rasburicase acts by catalyzing the oxidation of uric acid into allantoin, a more water-soluble and easily excretable compound, thereby reducing serum uric acid levels effectively and quickly. Its introduction has significantly improved the management of TLS, especially in high-risk patients. As a biotechnologically produced drug, Rasburicase is considered a significant advancement in supportive care for oncology patients
Mechanism of Action of Rasburicase:
Rasburicase is a recombinant urate oxidase enzyme that catalyzes the enzymatic oxidation of uric acid into allantoin, a highly water-soluble and easily excretable compound. This conversion significantly reduces the concentration of uric acid in the blood.
The mechanism occurs as follows:
1. Substrate: Uric acid (which is poorly soluble in water and tends to crystallize in renal tubules).
2. Enzymatic action: Rasburicase (urate oxidase) oxidizes uric acid.
3. Product: Allantoin + Hydrogen peroxide (H₂O₂) + Carbon dioxide (CO₂).
This reaction helps to rapidly lower plasma uric acid levels and is especially beneficial in patients with tumor lysis syndrome (TLS), where rapid cell breakdown releases large amounts of nucleic acids that are metabolized into uric acid.
Examples of Medication Brand Names
indication
Rasburicase is indicated for the treatment and prevention of hyperuricemia associated with tumor lysis syndrome (TLS), particularly in:
Pediatric and adult patients with hematologic malignancies (like leukemia or lymphoma) who are at high risk of developing TLS.
Patients with elevated baseline uric acid levels prior to chemotherapy, especially when rapid tumor breakdown is expected.
It helps prevent complications such as acute kidney injury caused by uric acid crystal deposition in the renal tubules
Side effect
Common Side Effects:
Fever
Headache
Nausea and vomiting
Abdominal pain
Constipation or diarrhea
Serious Side Effects:
Hypersensitivity reactions, such as rash, pruritus, bronchospasm, or even anaphylaxis.
Hemolysis, especially in patients with G6PD deficiency, which may lead to acute hemolytic anemia.
Methemoglobinemia, a condition where there is an increased level of methemoglobin in the blood, reducing its ability to carry oxygen.
Acute renal failure, rare but possible in cases associated with tumor lysis syndrome itself.
precautions
1. G6PD Deficiency:
Rasburicase must not be used in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency due to the risk of hemolytic anemia and methemoglobinemia.
G6PD testing should be performed prior to initiating treatment.
2. Monitoring of Blood Parameters:
Regular monitoring of uric acid levels, kidney function, and hemoglobin is necessary during treatment.
3. Allergic Reactions:
Patients should be monitored for potential severe hypersensitivity reactions such as rash, difficulty breathing, or anaphylaxis.
4. Use in Pregnancy and Lactation:
The safety of Rasburicase during pregnancy and breastfeeding has not been fully established. It should be used only if the potential benefit justifies the potential risk.
5. Handling of Blood Samples:
When analyzing uric acid levels, blood samples must be immediately cooled (placed on ice) to prevent ongoing Rasburicase activity outside the body, which may result in falsely low readings.
6. Pediatric and Geriatric Use:
Rasburicase is considered safe for use in children at recommended doses. Caution is advised in elderly patients due to the potential presence of comorbid condition
monograph
reference
1. Introduction about Rasburicase
https://go.drugbank.com/drugs/DB00082
2. Mechanism of Action
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103951s5140lbl.pdf
3. Brand Name Example (Elitek)
https://www.sanofi.com/en/your-health/elitek
4. Indications
https://www.nccn.org/professionals/physician_gls/pdf/tumor_lysis.pdf
→ NCCN Guidelines – استخدام Rasburicase في متلازمة تحلل الورم.
5. Side Effects
https://www.drugs.com/sfx/rasburicase-side-effects.html
→ Drugs.com – قائمة بالآثار الجانبية لـ Rasburicase.
6. Precautions
https://www.uptodate.com/contents/rasburicase-drug-information
Risedonate
Risedronate Sodium is the generic name of a medication that is marketed under various brand names, including Actonel and Risedronate. It is primarily used for the treatment and prevention of bone diseases that result from an imbalance between bone resorption and formation, leading to loss of bone mineral density.
Drug Class:
Risedronate belongs to a group of medications called bisphosphonates, which are potent anti-resorptive agents. These drugs slow down or prevent bone loss by acting on specific bone cells.
Mechanism of Bone Loss:
Under normal physiological conditions, there is a delicate balance between osteoblasts (bone-forming cells) and osteoclasts (bone-resorbing cells). In conditions like osteoporosis or due to aging, osteoclast activity increases, leading to accelerated bone breakdown. This is where Risedronate plays a therapeutic role — it inhibits osteoclast-mediated bone resorption, thereby helping to maintain or improve bone density.
Detailed Indications:
Postmenopausal women: Risedronate is used to prevent and treat osteoporosis, significantly reducing the risk of fractures, particularly in the spine and hip.
Glucocorticoid-induced osteoporosis: Long-term use of corticosteroids can lead to decreased bone density. Risedronate helps counteract this side effect.
Osteoporosis in men: Especially in older men or those with chronic medical conditions, Risedronate is effective in preserving bone mass.
Paget’s Disease of Bone: This condition is characterized by increased osteoclast activity, resulting in abnormally shaped or weakened bones. Risedronate helps regulate bone remodeling in such patients.
Duration of Use:
Risedronate is typically prescribed for several months to years, depending on the patient’s bone density results and clinical response to therapy.
Importance of Monitoring:
Regular bone mineral density tests (DEXA scans) are recommended to evaluate the effectiveness of treatment.
Additionally, kidney function tests and serum calcium levels may be periodically monitored, as bisphosphonates can affect renal function and calcium metabolism.
1. Absorption and Transport to Bone:
After oral administration, only a small fraction of the Risedronate dose (around 0.5% to 1%) is absorbed through the gastrointestinal tract.
It must be taken on an empty stomach with a full glass of water, as food or other medications can interfere with absorption.
Once absorbed, it travels directly through the bloodstream to bone tissue.
2. Binding to Hydroxyapatite in Bone:
Risedronate has a high affinity for bone surfaces, particularly areas undergoing active remodeling—such as stress-bearing sites or recent fractures.
It binds specifically to the mineral component of bone called hydroxyapatite (Ca₁₀(PO₄)₆(OH)₂).
3. Selective Inhibition of Osteoclasts (Bone-Resorbing Cells):
When osteoclasts attempt to resorb bone, they end up ingesting Risedronate that's bound to the bone surface.
Inside these cells, Risedronate disrupts key biochemical pathways responsible for energy production and enzyme activity.
4. Inhibition of the Mevalonate Pathway:
This is the critical step:
Risedronate inhibits a key enzyme known as Farnesyl Pyrophosphate Synthase (FPPS) within osteoclasts.
This enzyme is part of the Mevalonate Pathway, which is essential for producing molecules involved in:
Cell membrane synthesis
Intracellular signaling
Protein prenylation (important for cytoskeleton structure)
Inhibition leads to:
Loss of cytoskeletal function
Reduced cell adhesion to bone surface
Decreased secretion of bone-resorbing enzymes
Eventually, this triggers osteoclast apoptosis (programmed cell death).
5. Final Result:
Reduced number and activity of osteoclasts = decreased bone resorption
This allows osteoblasts (bone-building cells) to function more efficiently
Over time:
Increased bone mineral density (BMD)
Reduced risk of fractures, especially in the spine and hip
Examples of Medication Brand Names
indications
1. Osteoporosis
A. Postmenopausal Osteoporosis:
Purpose: To reduce the risk of vertebral and hip fractures.
Target group: Women after menopause who have low bone mineral density or a history of osteoporotic fractures.
B. Osteoporosis in Men:
Purpose: To increase bone density and reduce fracture risk.
Target group: Men with osteoporosis, especially those with risk factors such as low testosterone or chronic corticosteroid use.
2. Glucocorticoid-Induced Osteoporosis (Prevention and Treatment):
Purpose: To prevent loss of bone mass in patients taking long-term corticosteroids at high doses.
Target group: Men and women receiving ≥7.5 mg of prednisone (or equivalent) daily for over 3 months.
3. Paget’s Disease of Bone:
Purpose: To reduce bone turnover, relieve bone pain, and improve bone structure.
Signs: Elevated alkaline phosphatase (ALP) levels, bone deformities, or bone pain.
Dose: Usually 30 mg daily for 2 months.
Important Notes:
Contraindicated in patients with untreated hypocalcemia.
Should be taken on an empty stomach with a full glass of water, and the patient must remain upright for at least 30 minutes after the dose.
Effective only if the patient has adequate calcium and vitamin D levels.
side effect
Common Side Effects:
Stomach pain or indigestion
Nausea, constipation, or diarrhea
Bone, joint, or muscle pain
Headache
Serious (Rare) Side Effects:
Osteonecrosis of the jaw
Atypical femur fractures
Esophageal irritation or ulcers
Important Tips:
Take on an empty stomach with water, and stay upright for at least 30 minutes.
Ensure good calcium and vitamin D levels during treatment.
Contraindications
1. Hypocalcemia (Low blood calcium levels):
Risedronate must not be used if calcium levels are low.
Always correct hypocalcemia before starting the drug.
2. Inability to Sit or Stand Upright for at Least 30 Minutes:
Patients who cannot remain upright may be at increased risk of esophageal irritation or ulceration.
3. Esophageal Abnormalities:
Conditions such as esophageal stricture or achalasia that delay emptying of the esophagus.
Risk of severe esophagitis or ulcers if the tablet remains in the esophagus.
4. Hypersensitivity to Risedronate or Any of Its Components:
Includes allergic reactions such as rash, itching, or anaphylaxis.
5. Severe Renal Impairment:
Usually contraindicated if creatinine clearance <30 mL/min.
Drug may accumulate in the body and increase toxicity.
Optional Note:
Not an absolute contraindication, but use with caution in patients with:
Active upper GI problems (like ulcers or reflux)
Vitamin D deficiency
History of jaw problems or dental surgeries
Monograph
Refrences
Aprepit
Introduction
Aprepitant is a medication primarily used as an antiemetic, specifically to prevent nausea and vomiting associated with chemotherapy and surgery. It belongs to a class of drugs known as NK1 (neurokinin-1) receptor antagonists. By blocking the action of substance P, a neuropeptide involved in the vomiting reflex, aprepitant helps to manage and reduce the incidence of chemotherapy-induced nausea and vomiting (CINV), particularly in patients receiving highly emetogenic chemotherapy regimens.
MOA
The mechanism of action of aprepitant can be described in a step-by-step manner, highlighting its effects on the neurokinin-1 (NK1) receptors and the involvement of substance P in the emetic pathway.
Key Points About the Mechanism:
Target: NK1 receptors in the CNS
Inhibitor: Aprepitant acts as an antagonist, preventing activation by substance P.
Outcome: Reduced nausea and vomiting associated with chemotherapy and certain surgeries.
Examples of Medication Brand Names
Indication
Aprepitant is indicated primarily for the prevention of nausea and vomiting. Here are the specific indications for its use:
Chemotherapy-Induced Nausea and Vomiting (CINV): Aprepitant is used in combination with other antiemetic medications for the prevention of both acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy (chemotherapy agents that are highly likely to induce vomiting) and moderate emetogenic chemotherapy.
Postoperative Nausea and Vomiting (PONV): Aprepitant can be used to prevent nausea and vomiting following surgery, particularly in patients who are at high risk for developing PONV.
Combination with Other Antiemetics: Aprepitant is often prescribed alongside other antiemetic agents, such as 5-HT3 receptor antagonists (e.g., ondansetron) and corticosteroids (e.g., dexamethasone), to enhance overall efficacy in preventing nausea and vomiting.
Side Effects
Common Side Effects:
Fatigue: Many patients report feeling tired or fatigued while taking aprepitant.
Dizziness: Some individuals may experience dizziness or lightheadedness.
Gastrointestinal Disturbances: This can include nausea, vomiting, diarrhea, or constipation.
Loss of Appetite: Changes in appetite can occur in some patients.
Precautions & Contraindications
Precautions:
Liver Impairment:
Aprepitant is metabolized by the liver. Caution is advised in patients with liver dysfunction, and dosage adjustments may be necessary.
Drug Interactions:
Aprepitant can interfere with the metabolism of other medications due to its effects on CYP3A4 enzymes. It is essential to inform healthcare providers about all medications (prescription and over-the-counter) being taken to assess potential interactions.
Pregnancy and Breastfeeding:
The safety of aprepitant during pregnancy and breastfeeding has not been established. It should only be used if the potential benefits outweigh the risks, and patients should consult their healthcare provider.
History of Allergic Reactions:
Patients with a history of hypersensitivity or allergies to aprepitant or any of its components should avoid using the medication.
Elderly Patients:
Caution may be warranted in elderly patients due to the potential for increased sensitivity to side effects and the likelihood of concurrent health issues.
Contraindications:
Hypersensitivity:
Aprepitant is contraindicated in patients who have a known hypersensitivity to aprepitant or to any component of the formulation.
Concurrent Use with Certain Medications:
Aprepitant should not be used with certain drugs that are primarily metabolized by CYP3A4, where inhibition could lead to unsafe levels. This includes certain medications used for controlling HIV, seizures, and other serious conditions.
Severe Liver Disease:
Patients with severe liver impairment (Child-Pugh Class C) should avoid aprepitant due to alteration in drug metabolism.
Monograph
Refrences
Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by
Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the
action of endothelin molecules that would otherwise promote narrowing of the blood vessels and
lead to high blood pressure.
Early Development
Originated by Roche (now Actelion Pharmaceuticals), bosentan was first studied in the 1990s for
conditions like heart failure and asthma. The REACH-1 trial (1997) was terminated early due to
toxicity at high doses.
MOA
Bosentan is a dual endothelin receptor antagonist used to treat pulmonary arterial hypertension (PAH). It works by blocking both ETA and ETB receptors that bind endothelin-1 (ET-1), a substance that causes vasoconstriction, cell proliferation, and inflammation.
ETA receptor blockade reduces vasoconstriction and smooth muscle cell proliferation.
ETB receptor blockade may decrease vasodilation and ET-1 clearance, but the net effect remains beneficial.
Therapeutic effects include:
1.Lower pulmonary artery pressure
2.Improved blood flow
3.Prevention of vascular remodeling
4.Better exercise capacity and reduced PAH symptoms
Example of medication
Indications
Bosentan is primarily indicated for the treatment of:
Pulmonary Arterial Hypertension (PAH)
To improve exercise capacity and decrease clinical worsening in patients with WHO Functional Class II–IV.
Other off-label or less common indications may include:
Digital ulcers in systemic sclerosis (to reduce the number of new ulcers)
Pulmonary fibrosis in scleroderma (investigational/under evaluation)
side effect
Bosentan, an endothelin receptor antagonist used to
treat pulmonary arterial hypertension (PAH), is
associated with several side effects. While it is
generally well-tolerated, some side effects can be serious
and require close monitoring. Below is a detailed list of
the common and serious side effects of bosentan:
Common Side Effects:
These side effects are generally mild to moderate and
may improve with continued use:
1. Headache
2. Peripheral Edema
3. Flushing
4. Nasopharyngitis
5. Dizziness
6. Gastrointestinal Issues
7. Fatigue
8. Upper Respiratory Tract Infections
Serious Side Effects:
These side effects require immediate medical attention:
1. Hepatotoxicity (Liver Damage)
2. Anemia
3. Fluid Retention and Heart Failure
4. Hypotension (Low Blood Pressure)
Precautions and Contraindication
Precautions
1. Hepatotoxicity
Liver function abnormalities are common.
Regular liver function tests (LFTs) are required—monthly monitoring is recommended.
Discontinue or adjust the dose if aminotransferase levels rise significantly.
2. Teratogenicity
Bosentan is contraindicated in pregnancy due to risk of birth defects.
Effective contraception is required for women of childbearing potential, and monthly pregnancy tests are recommended.
3. Hemoglobin Decrease
Can cause a dose-related decrease in hemoglobin and hematocrit.
Monitor hemoglobin levels, especially during the first few months.
4. Drug Interactions
CYP3A4 and CYP2C9 inducer: May reduce effectiveness of drugs metabolized by these enzymes (e.g., hormonal contraceptives, warfarin).
May reduce effectiveness of hormonal birth control, so dual contraception is recommended.
5. Fluid Retention
May cause fluid retention or worsening of heart failure in susceptible patients.
Monitor weight and signs of edema.
Contraindications:
Pregnancy
Bosentan is teratogenic and must not be used during pregnancy.
Women of childbearing potential must use reliable contraception.
Hypersensitivity
Contraindicated in patients with known hypersensitivity to bosentan or any of its components.
Liver Impairment
Moderate to severe hepatic impairment or elevated liver aminotransferases (>3× upper limit of normal) at baseline.
Concomitant Use with Cyclosporine A
Bosentan is contraindicated with cyclosporine A due to the risk of serious drug interactions and elevated bosentan levels.
Monograph
Refrences
By :
Ahmed Hossam Ibrahim Ismail
Calcitonin is a peptide hormone composed of 32 amino acids. It is primarily produced by the parafollicular cells (also known as C cells) of the thyroid gland in mammals.
Main Function:
Calcitonin plays an important role in regulating calcium levels in the blood by lowering them. It acts in opposition to parathyroid hormone (PTH). Its main actions include:
1. Inhibiting osteoclast activity in bones – Osteoclasts are cells that break down bone tissue and release calcium into the bloodstream. Calcitonin reduces their activity, thereby preventing calcium release from bones.
2. Increasing calcium excretion by the kidneys – It enhances the amount of calcium excreted in urine, helping to lower blood calcium levels.
3. Reducing calcium absorption in the intestines – Though this is a less significant effect compared to the other two.
Presence in Animals:
Calcitonin is found in various vertebrates including:
Fish
Reptiles
Birds
Mammals
Interestingly, salmon calcitonin has been used in medicine because it is more potent and longer-lasting than human calcitonin.
Clinical Use:
Calcitonin can be used as a medication in the treatment of:
Osteoporosis
Paget’s disease of bone
Hypercalcemia (high calcium levels in the blood)
It can be administered via injection or nasal spray.
1. Effect on Bones:
Calcitonin is secreted by the C cells of the thyroid gland in response to elevated blood calcium levels.
It acts by binding to specific receptors on the surface of osteoclasts, the cells responsible for bone resorption (the breakdown of bone tissue).
Once bound, calcitonin inhibits osteoclast activity, leading to:
Decreased bone resorption.
Reduced release of calcium and phosphate from bones into the bloodstream.
A reduction in both the number and activity of osteoclasts over time.
2. Effect on Kidneys:
Calcitonin decreases the renal tubular reabsorption of calcium and phosphate, particularly in the proximal and distal tubules.
This leads to increased urinary excretion of calcium and phosphate, contributing to a lowering of their blood levels.
3. Overall Effect:
The net result of calcitonin action is a **reduction in blood calcium level
Example of medication
Indications
Calcitonin has been used in the treatment of various bone-related and metabolic conditions. Its primary indications include:
1. Postmenopausal Osteoporosis:
Used to reduce the rate of bone loss and increase bone mineral density, particularly in women who are more than five years postmenopausal.
It may also help relieve bone pain associated with vertebral fractures.
2. Paget’s Disease of Bone:
Helps to regulate abnormal bone remodeling by inhibiting excessive osteoclastic activity.
Effective in relieving bone pain and reducing bone turnover markers.
3. Bone Metastases:
Used to manage bone pain and limit bone destruction caused by metastatic cancer, especially in cases with high osteoclastic activity.
4. Hypercalcemia:
Employed as an emergency treatment for acute hypercalcemia due to its rapid action in lowering serum calcium levels.
Especially useful in malignancy-associated hypercalcemia.
5. Phantom Limb Pain:
Has been reported to alleviate pain in patients suffering from phantom limb syndrome, possibly through central modulation of pain pathways.
6. Vertebral Fractures:
Provides short-term pain relief in patients with recent vertebral compression fractures, often used as part of supportive therapy in osteoporosis.
Side Effects
Calcitonin is generally well-tolerated, but it may cause some side effects, which can vary depending on the route of administration (injection or nasal spray).
Common Side Effects:
Injection-related:
Red streaks on the skin
Swelling, tenderness, or pain at the injection site
Nasal spray-related:
Nasal irritation (e.g., dryness, soreness, or congestion
Nausea
Flushing of the skin
Less Common Side Effects:
A general feeling of warmth
Redness of the face, neck, arms, and occasionally the upper chest
Dizziness or lightheadedness (rare)
Allergic reactions (rash, itching, or in rare cases, anaphylaxis)
Contraindications
Contraindications:
Hypersensitivity to calcitonin-salmon or to any component of the formulation.
This includes a history of serious allergic reactions, such as anaphylaxis, to salmon-derived products.
Cautions:
Risk of Hypocalcemia:
Calcitonin can lower blood calcium levels; therefore, serum calcium should be monitored regularly during treatment.
Ensure adequate calcium and vitamin D intake to minimize this risk.
Renal Impairment:
Use with caution in patients with impaired kidney function, as altered calcium and phosphate handling may affect drug response or safety.
Hypersensitivity Reactions:
Though rare, serious allergic reactions may occur. A skin test may be recommended before initiating therapy in at-risk individuals.
monograph
Refrences
1-Luboshitzky R, Bar-Shalom R. [Calcitonin nasal spray for Paget's disease of the bone]. Harefuah. 1995 Mar 15;128(6):358-62, 399. [https://pubmed.ncbi.nlm.nih.gov/7750816/]
2-Wisneski LA. Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int. 1990;46 Suppl:S26-30. [https://pubmed.ncbi.nlm.nih.gov/2137363/] 3-Reginster JY, Franchimont P. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol. 1985 Apr-Jun;3(2):155-7. [https://pubmed.ncbi.nlm.nih.gov/2410171/]
2-Wisneski LA. Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int. 1990;46 Suppl:S26-30. [https://pubmed.ncbi.nlm.nih.gov/2137363/] 3-Reginster JY, Franchimont P. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol. 1985 Apr-Jun;3(2):155-7. [https://pubmed.ncbi.nlm.nih.gov/2410171/]
By:Asmaa Mahmoud Elsaeed
Introduction
Dantrolene Sodium is a hydantoin derivative classified as a direct-acting skeletal muscle relaxant.
It is the only drug specifically approved for the treatment and prevention of malignant hyperthermia (MH), a rare but lethal pharmacogenetic disorder triggered by certain anesthetics and muscle relaxants.
It is also used for chronic spasticity arising from neurological conditions without central sedation.
Chemical formula: C₁₄H₁₀N₄O₅
Molecular Weight: 314.26 g/mol
Illustrated Mechanism of Action
In normal muscle physiology, electrical stimulation leads to calcium release via the ryanodine receptor (RYR1), initiating contraction.
In patients susceptible to MH, mutations cause uncontrolled calcium release, leading to hypermetabolism, acidosis, and heat generation.
Dantrolene acts by:
Binding to RYR1 receptors.
Inhibiting abnormal calcium release.
Preventing the sustained muscle contractions and hypermetabolism.
Effects
↓ Skeletal muscle contraction
↓ Muscle rigidity
↓ Heat production
↓ Oxygen consumption
↓ CO₂ production
important:
Dantrolene does not significantly affect cardiac or smooth muscles because they utilize different calcium channels (L-type calcium channels).
Examples of Medication Brand Names (with Images)
4. Indications
Approved indications:
Treatment of acute malignant hyperthermia during surgery or anesthesia.
Prophylactic use in high-risk surgical patients.
Management of chronic spasticity in:
Stroke
Multiple sclerosis
Cerebral palsy
Spinal cord injury
Off-Label uses:
Neuroleptic malignant syndrome (NMS)
Ecstasy (MDMA)-induced hyperthermia
Baclofen withdrawal syndrome (in ICU settings)
5. Side Effects
Very Common (>10%):
Drowsiness
Muscle weakness
Fatigue
Diarrhea
Common (1-10%):
Dizziness
Nausea
Difficulty swallowing
Speech disturbances
Visual disturbances (e.g., blurred vision)
Rare (<1%):
Hepatitis (potentially fatal)
Seizures
Severe allergic reactions (anaphylaxis)
Respiratory depression (especially with overdose)
Black Box Warning:
Risk of fatal hepatotoxicity, especially in females >35 years old receiving long-term therapy.
Precautions & Contraindications
Precautions:
Monitor liver function (AST, ALT, bilirubin) before and during therapy.
Use cautiously in patients with respiratory muscle weakness (e.g., myasthenia gravis).
Adjust dose in elderly patients.
Monitor for signs of CNS depression.
Contraindications:
Active hepatic disease.
Known hypersensitivity to Dantrolene.
Patients requiring full muscular strength (e.g., in rehabilitation phases).
Monograph
Refrences
https://go.drugbank.com/drugs/DB01219
https://www.ncbi.nlm.nih.gov/books/NBK535398/
Introduction
Introduction to Levosimendan:
Levosimendan is a calcium sensitizer and potassium channel opener used primarily in the treatment of acute decompensated heart failure. It enhances cardiac contractility without significantly increasing myocardial oxygen demand, making it a valuable option for patients with reduced ejection fraction.
MOA
Levosimendan is a calcium sensitizer and potassium channel opener used primarily to treat acute decompensated heart failure. Here's its mechanism of action (MOA) broken down simply:
Levosimendan binds to cardiac troponin C in a calcium-dependent manner.
This increases the sensitivity of the heart muscle to calcium, which enhances myocardial contractility without increasing intracellular calcium (unlike traditional inotropes).
Result: Stronger heart contractions with less risk of arrhythmias or increased oxygen demand.
Levosimendan opens ATP-sensitive potassium (K⁺) channels in:
Vascular smooth muscle → leading to vasodilation
Mitochondria in cardiac cells → possibly providing cardioprotective effects
Result: Decreased preload and afterload, reducing the work of the failing heart.
Examples of Medication Brand Names
indication
Indications of Levosimendan
Levosimendan is primarily indicated for the short-term treatment of acutely decompensated severe chronic heart failure when conventional therapy is not sufficient, and in cases where inotropic support is deemed necessary.
Side effects
Side Effects of Levosimendan
Levosimendan is generally well tolerated but, like all medications, it can cause side effects — especially due to its inotropic and vasodilatory actions.
Precautions and Contraindications
Precautions and Contraindications of Levosimendan
⸻
Precautions:
Levosimendan should be used with careful monitoring in the following situations:
1. Hypotension or Low Blood Volume:
• Due to its vasodilatory effects, it may worsen hypotension.
• Correct hypovolemia before administration.
2. Tachyarrhythmias:
• Can increase heart rate or precipitate arrhythmias.
• Monitor ECG closely during infusion.
Monograph
Refrences
Introduction
Introduction
Ivacaftor is a groundbreaking medication developed to treat cystic fibrosis (CF) in individuals with specific mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Cystic fibrosis is a genetic disorder that primarily affects the lungs, but also impacts other organs such as the pancreas, liver, and intestines. Ivacaftor helps improve the function of the defective CFTR protein, addressing the underlying cause of the disease.
MOA
Ivacaftor is a CFTR potentiator. In patients with specific CFTR mutations, the CFTR protein is often present at the cell surface but does not function properly. Ivacaftor works by binding to the CFTR protein and facilitating its opening, which enhances chloride ion transport across the cell membrane. This improved chloride transport helps to hydrate the airway surfaces, thinning the mucus and making it easier to clear from the lungs. (Include an image illustrating this mechanism, showing the CFTR protein, its mutation, and how Ivacaftor binds to and opens the channel)
Examples of Medication Brand Names
Indication
Indication
Ivacaftor is indicated for the treatment of cystic fibrosis in patients aged 1 month and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, A455E, D1152H, E56K, F1052V, R117H, or R347H. The use of Ivacaftor should be guided by genetic testing to confirm the presence of one of these responsive mutations.
Side Effects
Common side effects associated with Ivacaftor include:
* Headache
* Stomach pain
* Diarrhea
* Rash
* Dizziness
* Upper respiratory tract infection
* Nasal congestion
Less common but potentially serious side effects include:
* Liver enzyme elevations
* Cataracts (especially in children)
Precautions and Contraindications
Precautions and Contraindications
* *Hepatic Impairment:* Ivacaftor should be used with caution in patients with moderate or severe hepatic impairment. Dosage adjustments may be necessary.
* *Drug Interactions:* Ivacaftor is a substrate of CYP3A enzymes, and its levels can be affected by strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) and inducers (e.g., rifampin, St. John's Wort).
* *Pregnancy and Breastfeeding:* There is limited data on the use of Ivacaftor in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Ivacaftor is excreted in human milk, so caution should be exercised when administered to a breastfeeding woman.
* *Cataracts:* Cases of non-congenital lens opacities/cataracts have been reported in pediatric patients treated with Ivacaftor. Baseline and follow-up ophthalmological examinations are recommended in pediatric patients initiating treatment with Ivacaftor.
Monograph
References
Kalydeco (Ivacaftor) Official Website: https://www.kalydeco.com/
FDA - Kalydeco Prescribing Information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203123lbl.pdf
European Medicines Agency (EMA) - Kalydeco: https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco
PubMed - Ivacaftor: https://pubmed.ncbi.nlm.nih.gov/ (Use this link to search for scientific articles on Ivacaftor)
Cystic Fibrosis Foundation: https://www.cff.org/
Introduction
Introduction Rifampin is a broad-spectrum antibiotic from the rifamycin group. It is widely used in the treatment of tuberculosis, leprosy, and other infections caused by susceptible bacteria. It is known for its ability to penetrate tissues and biofilms effectively.
MOA
Rifampin works by inhibiting bacterial DNA-dependent RNA polymerase. This blocks RNA transcription and prevents the bacteria from synthesizing essential proteins.
Examples of Medication Brand Names
Indication
- Tuberculosis (in combination with other drugs)
- Leprosy
- Prophylaxis for meningococcal meningitis
- Brucellosis
- Endocarditis (off-label)
Side Effects
- Orange-red discoloration of body fluids
- Nausea, vomiting
- Diarrhea
Precautions & Contraindications
Precautions: - Monitor liver function tests regularly during treatment - Use caution in patients with hepatic impairment Contraindications: - Hypersensitivity to rifampin or other rifamycins - Concurrent use with certain antiretroviral agents (e.g., protease inhibitors)
Monograph
References
Introduction
Eculizumab is a humanized monoclonal antibody used to treat rare, life-threatening autoimmune conditions.
It works by inhibiting the complement system — a part of the immune system that normally helps fight infections but can also attack the body’s own cells in certain diseases.
The drug is manufactured by Alexion Pharmaceuticals and marketed under the brand name Soliris. It’s administered via intravenous infusion.
MOA
The complement system includes a cascade of proteins (C1 to C9) that help kill harmful cells.
One of the key proteins is C5. When activated, C5 splits into C5a and C5b — leading to the formation of the Membrane Attack Complex (MAC), which punches holes in cell membranes.
Eculizumab binds to C5, blocking its cleavage into C5a and C5b, which prevents MAC formation, thus protecting cells (especially red blood cells and nerve tissues) from immune damage.
Examples of Medication Brand Names
Indication
Eculizumab is approved for several rare autoimmune diseases:
1. Paroxysmal Nocturnal Hemoglobinuria (PNH):
A disorder where red blood cells break apart (hemolysis) due to lack of complement protection.
2. Atypical Hemolytic Uremic Syndrome (aHUS):
A condition involving hemolysis, kidney damage, and blood clots due to abnormal complement activation.
3. Generalized Myasthenia Gravis (gMG):
An autoimmune disorder causing muscle weakness by attacking neuromuscular junctions.
4. Neuromyelitis Optica Spectrum Disorder (NMOSD):
A disease causing inflammation in the optic nerves and spinal cord.
Side effects
Common side effects:
Headache
Nausea
Fatigue
Joint pain
Upper respiratory tract infections
Serious risks:
Meningococcal infection (very serious; can be fatal)
That’s why patients must receive a meningococcal vaccine at least 2 weeks before starting the drug.
Precautions & Contraindications
Precautions:
Must be vaccinated against Neisseria meningitidis before therapy.
Monitor for signs of infection during treatment.
Infusion reactions may occur — administer under supervision.
Don't stop treatment suddenly — it can cause disease relapse.
Contraindications:
Active serious infections
Known hypersensitivity to Eculizumab or its components
Monograph
References